Study finds GLP-1 weight-loss drugs appear safe and effective for children with severe obesity

A transplant surgeon and obesity‑medicine specialist at NYU Langone reports that his research on GLP-1 weight‑loss drugs in children yields reassuring results. He notes that many of his transplant patients are now younger, with organ failure often linked to childhood obesity.

The article cites data showing adolescents with severe obesity are up to nine times more likely to develop chronic kidney disease in early adulthood, even without diabetes or hypertension. It also highlights that childhood fatty liver disease raises mortality risk by about 40‑fold and has become a leading cause of liver transplants in young adults.

The author emphasizes that GLP-1 medications are already changing lives for kids who need them, offering a potential way to intervene before organ damage occurs. He argues that early treatment could reduce the long‑term burden of obesity‑related organ failure.

While cautioning against alarmist messaging, he stresses that with roughly 20% of U.S. children affected by obesity, the medical community cannot ignore the growing health consequences and should consider GLP-1 therapy as part of a broader prevention strategy.